ADCT - ADC Therapeutics Non-GAAP EPS of -$0.38 revenue of $17.8M misses by $0.32M May, 06 2024 06:13 AM ADC Therapeutics SA 2024-05-06 06:13:21 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics gains after data for lymphoma therapy Seeking Alpha’s Quant Rating on ADC Therapeutics For further details see: ADC Therapeutics Non-GAAP EPS of -$0.38, revenue of $17.8M misses by $0.32M